JP7145849B2 - 新規の製剤 - Google Patents

新規の製剤 Download PDF

Info

Publication number
JP7145849B2
JP7145849B2 JP2019517947A JP2019517947A JP7145849B2 JP 7145849 B2 JP7145849 B2 JP 7145849B2 JP 2019517947 A JP2019517947 A JP 2019517947A JP 2019517947 A JP2019517947 A JP 2019517947A JP 7145849 B2 JP7145849 B2 JP 7145849B2
Authority
JP
Japan
Prior art keywords
formulation
zinc
insulin
concentration
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019517947A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533656A (ja
JP2019533656A5 (https=
Inventor
ジェリング デビッド
ハウエル サラ
ジェゼク ジャン
ザクルゼウスキ レオン
Original Assignee
アレコル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1616509.4A external-priority patent/GB201616509D0/en
Priority claimed from GBGB1617866.7A external-priority patent/GB201617866D0/en
Priority claimed from GBGB1707190.3A external-priority patent/GB201707190D0/en
Application filed by アレコル リミテッド filed Critical アレコル リミテッド
Publication of JP2019533656A publication Critical patent/JP2019533656A/ja
Publication of JP2019533656A5 publication Critical patent/JP2019533656A5/ja
Priority to JP2022148894A priority Critical patent/JP2022180499A/ja
Application granted granted Critical
Publication of JP7145849B2 publication Critical patent/JP7145849B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/3159—Dose expelling manners
    • A61M5/31591—Single dose, i.e. individually set dose administered only once from the same medicament reservoir, e.g. including single stroke limiting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/3159—Dose expelling manners
    • A61M5/31593—Multi-dose, i.e. individually set dose repeatedly administered from the same medicament reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019517947A 2016-09-29 2017-09-29 新規の製剤 Active JP7145849B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022148894A JP2022180499A (ja) 2016-09-29 2022-09-20 新規の製剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1616509.4A GB201616509D0 (en) 2016-09-29 2016-09-29 Novel formulations
GB1616509.4 2016-09-29
GBGB1617866.7A GB201617866D0 (en) 2016-10-21 2016-10-21 Novel formulations
GB1617866.7 2016-10-21
GBGB1707190.3A GB201707190D0 (en) 2017-05-05 2017-05-05 Novel Formulations
GB1707190.3 2017-05-05
PCT/GB2017/052940 WO2018060735A1 (en) 2016-09-29 2017-09-29 Novel formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022148894A Division JP2022180499A (ja) 2016-09-29 2022-09-20 新規の製剤

Publications (3)

Publication Number Publication Date
JP2019533656A JP2019533656A (ja) 2019-11-21
JP2019533656A5 JP2019533656A5 (https=) 2020-11-12
JP7145849B2 true JP7145849B2 (ja) 2022-10-03

Family

ID=60037644

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2019517947A Active JP7145849B2 (ja) 2016-09-29 2017-09-29 新規の製剤
JP2019517968A Pending JP2019529506A (ja) 2016-09-29 2017-09-29 新規の製剤
JP2022132329A Pending JP2022176989A (ja) 2016-09-29 2022-08-23 新規の製剤
JP2022148894A Pending JP2022180499A (ja) 2016-09-29 2022-09-20 新規の製剤
JP2024110933A Pending JP2024153677A (ja) 2016-09-29 2024-07-10 新規の製剤

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019517968A Pending JP2019529506A (ja) 2016-09-29 2017-09-29 新規の製剤
JP2022132329A Pending JP2022176989A (ja) 2016-09-29 2022-08-23 新規の製剤
JP2022148894A Pending JP2022180499A (ja) 2016-09-29 2022-09-20 新規の製剤
JP2024110933A Pending JP2024153677A (ja) 2016-09-29 2024-07-10 新規の製剤

Country Status (13)

Country Link
US (3) US20190282667A1 (https=)
EP (3) EP3518893A1 (https=)
JP (5) JP7145849B2 (https=)
KR (1) KR102482664B1 (https=)
CN (2) CN109803639B (https=)
AU (2) AU2017334289B2 (https=)
CA (2) CA3034971C (https=)
DK (1) DK3518892T5 (https=)
ES (1) ES2954180T3 (https=)
IL (1) IL265609B2 (https=)
MX (1) MX2019003611A (https=)
PL (1) PL3518892T3 (https=)
WO (2) WO2018060736A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
DK3518892T5 (da) * 2016-09-29 2024-09-02 Arecor Ltd Farmaceutisk formulering, der indeholder en insulinforbindelse
GB201707188D0 (en) * 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
IL277721B2 (en) 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
CA3094304A1 (en) * 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
CN112040928A (zh) * 2018-04-04 2020-12-04 艾瑞克有限公司 用于递送胰岛素化合物的医用输注泵系统
FR3084586B1 (fr) * 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
WO2020190591A1 (en) * 2019-03-15 2020-09-24 Eli Lilly And Company Preserved formulations
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations
EP4281039A2 (en) * 2021-01-25 2023-11-29 Mylan Ireland Limited Pharmaceutical glp peptide compositions and methods of preparation thereof
CN114887039B (zh) * 2022-05-13 2026-01-30 西北工业大学 一种锌离子介导的自组装胰岛素纳米药物、制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012531431A (ja) 2009-06-25 2012-12-10 イージス セラピューティクス リミテッド ライアビリティ カンパニー 安定化アルキルグリコシド組成物およびその方法
WO2016100042A1 (en) 2014-12-16 2016-06-23 Eli Lilly And Company Rapid-acting insulin compositions

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
JP3122128B2 (ja) 1989-12-21 2001-01-09 ノボ ノルディスク アクティーゼルスカブ ペプチド製剤
AU3562195A (en) 1994-10-04 1996-04-26 Novo Nordisk A/S Preparations containing aspb28 human insulin and nicotinamide
WO1997017945A2 (en) 1995-11-13 1997-05-22 Minimed, Inc. Methods and compositions for the delivery of monomeric proteins
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
DK1283051T3 (da) 1997-06-13 2006-10-16 Lilly Co Eli Stabile insulinformuleringer
EP1044016B1 (en) 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
DE602005014962D1 (de) 2004-03-12 2009-07-30 Biodel Inc Insulinzusammensetzungen mit verbesserter wirkstoffabsorption
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
WO2006051103A2 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of peptides
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
JP2009512709A (ja) 2005-10-20 2009-03-26 エムディーアールエヌエー，インコーポレイテッド 速効型インスリンの経鼻投与
CN101340893B (zh) * 2005-10-20 2012-03-21 玛瑞纳生物技术有限公司 速效胰岛素的鼻内施用
WO2007121256A2 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2007149096A1 (en) * 2006-06-23 2007-12-27 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
WO2009114959A1 (zh) * 2008-03-20 2009-09-24 中国人民解放军军事医学科学院毒物药物研究所 可注射用缓释药物制剂及其制备方法
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
WO2010115819A1 (en) 2009-03-31 2010-10-14 Sanofi-Aventis Deutschland Gmbh Mounting arrangement and coupling assembly for a drug-delivery device
AU2010264636B2 (en) 2009-06-26 2013-06-27 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and an amino acid
CN101912600B (zh) 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
WO2011094632A1 (en) * 2010-01-29 2011-08-04 The Uab Research Foundation Method for administration of insulin and pharmaceutical composition thereof
US20120178675A1 (en) 2010-07-07 2012-07-12 Biodel Inc. Compositions And Methods For Modulating The Pharmacokinetics and Pharmacodynamics of Insulin
JP2013545782A (ja) 2010-12-14 2013-12-26 ノヴォ ノルディスク アー／エス 長時間作用型インスリンと組み合わせた速効型インスリン
JP5950477B2 (ja) 2011-08-10 2016-07-13 アドシア 少なくとも１種の基礎インスリンの注射溶液
WO2013067022A1 (en) * 2011-10-31 2013-05-10 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
EP3130347B1 (en) 2011-12-30 2019-09-18 Halozyme, Inc. Ph20 polypeptide variants, formulations and uses thereof
US9381247B2 (en) 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
WO2013186138A1 (en) 2012-06-14 2013-12-19 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and arginine
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
US9707275B2 (en) * 2012-12-19 2017-07-18 Wockhardt Limited Stable aqueous composition comprising human insulin or an analogue or derivative thereof
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
AR098168A1 (es) 2013-10-25 2016-05-04 Sanofi Sa Formulación estable de insulina glulisina
US9895423B2 (en) * 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
JP6723921B2 (ja) * 2014-01-09 2020-07-15 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
GB2525838B (en) 2014-01-30 2020-12-30 Insulet Netherlands B V Actuator and actuation method
WO2015120457A1 (en) 2014-02-10 2015-08-13 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations
TWI685348B (zh) 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020952B1 (fr) 2014-05-14 2017-09-08 Adocia Formulation a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
DK3518892T5 (da) 2016-09-29 2024-09-02 Arecor Ltd Farmaceutisk formulering, der indeholder en insulinforbindelse
JP2018140127A (ja) 2017-02-28 2018-09-13 株式会社三洋物産 遊技機
GB201707189D0 (en) * 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
CN112040928A (zh) 2018-04-04 2020-12-04 艾瑞克有限公司 用于递送胰岛素化合物的医用输注泵系统
CA3094304A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
IL277721B2 (en) 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012531431A (ja) 2009-06-25 2012-12-10 イージス セラピューティクス リミテッド ライアビリティ カンパニー 安定化アルキルグリコシド組成物およびその方法
WO2016100042A1 (en) 2014-12-16 2016-06-23 Eli Lilly And Company Rapid-acting insulin compositions

Also Published As

Publication number Publication date
CN109803639B (zh) 2024-01-02
KR20190060788A (ko) 2019-06-03
US12527845B2 (en) 2026-01-20
US20260102473A1 (en) 2026-04-16
US20190290737A1 (en) 2019-09-26
JP2019533656A (ja) 2019-11-21
CN109803639A (zh) 2019-05-24
IL265609B1 (en) 2023-10-01
CA3034971C (en) 2025-07-08
MX2019003611A (es) 2019-06-17
JP2019529506A (ja) 2019-10-17
AU2017334290A1 (en) 2019-03-21
WO2018060735A1 (en) 2018-04-05
JP2022180499A (ja) 2022-12-06
JP2022176989A (ja) 2022-11-30
DK3518892T5 (da) 2024-09-02
AU2017334289B2 (en) 2023-04-20
PL3518892T3 (pl) 2023-11-27
AU2017334290B2 (en) 2023-04-20
JP2024153677A (ja) 2024-10-29
EP3518893A1 (en) 2019-08-07
EP3518892A1 (en) 2019-08-07
CA3034971A1 (en) 2018-04-05
EP4265296A2 (en) 2023-10-25
IL265609B2 (en) 2024-02-01
EP4265296A3 (en) 2023-12-20
AU2017334289A1 (en) 2019-03-21
IL265609A (en) 2019-05-30
EP3518892B1 (en) 2023-06-21
CA3034972C (en) 2024-04-09
ES2954180T3 (es) 2023-11-20
CN109789088A (zh) 2019-05-21
KR102482664B1 (ko) 2022-12-29
WO2018060736A1 (en) 2018-04-05
CA3034972A1 (en) 2018-04-05
US20190282667A1 (en) 2019-09-19
DK3518892T3 (da) 2023-07-31

Similar Documents

Publication Publication Date Title
JP7145849B2 (ja) 新規の製剤
CN110582285B (zh) 稳定的胰岛素制剂
JP7465813B2 (ja) インスリン化合物の送達のための医療用注入ポンプシステム
CN121868228A (zh) 包含聚山梨酯80的胰岛素制剂
JP2023071660A (ja) 新規の製剤
CN112040928A (zh) 用于递送胰岛素化合物的医用输注泵系统
US12357562B2 (en) Injection pen system for the delivery of an insulin compound
HK40013219B (en) Pharmaceutical formulation comprising an insulin compound

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220711

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220823

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220920

R150 Certificate of patent or registration of utility model

Ref document number: 7145849

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250